| Seizure disorders in patients with brain tumors A Liigant, S Haldre, A Õun, Ü Linnamägi, A Saar, T Asser, AE Kaasik European neurology 45 (1), 46-51, 2001 | 150 | 2001 |
| Cerebral hemodynamic impairment after aneurysmal subarachnoid hemorrhage as evaluated using transcranial Doppler ultrasonography: relationship to delayed cerebral ischemia and … T Rätsep, T Asser Journal of neurosurgery 95 (3), 393-401, 2001 | 119 | 2001 |
| Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system T Teesalu, A Kulla, A Simisker, V Sirén, DA Lawrence, T Asser, A Vaheri Thrombosis and haemostasis 92 (08), 358-368, 2004 | 115 | 2004 |
| Irreversible motor impairment in young addicts–ephedrone, manganism or both? K Sikk, P Taba, S Haldre, J Bergquist, D Nyholm, G Zjablov, T Asser, ... Acta Neurologica Scandinavica 115 (6), 385-389, 2007 | 89 | 2007 |
| Peptide-guided nanoparticles for glioblastoma targeting P Säälik, P Lingasamy, K Toome, I Mastandrea, L Rousso-Noori, A Tobi, ... Journal of Controlled Release 308, 109-118, 2019 | 85 | 2019 |
| High incidence of traumatic spinal cord injury in Estonia L Sabre, G Pedai, T Rekand, T Asser, Ü Linnamägi, J Kõrv Spinal cord 50 (10), 755-759, 2012 | 75 | 2012 |
| Epidemiology of primary central nervous system tumors in Estonia A Liigant, T Asser, A Kulla, AE Kaasik Neuroepidemiology 19 (6), 300-311, 2000 | 64 | 2000 |
| Relationship between neovascularization and degenerative changes in herniated lumbar intervertebral discs T Rätsep, A Minajeva, T Asser European Spine Journal 22, 2474-2480, 2013 | 63 | 2013 |
| Tissue plasminogen activator as a key effector in neurobiology and neuropathology T Teesalu, A Kulla, T Asser, M Koskiniemi, A Vaheri Biochemical Society Transactions 30 (2), 183-189, 2002 | 63 | 2002 |
| Tumor-penetrating peptide for systemic targeting of Tenascin-C P Lingasamy, A Tobi, K Kurm, S Kopanchuk, A Sudakov, M Salumäe, ... Scientific Reports 10 (1), 5809, 2020 | 60 | 2020 |
| The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury H Shakur, P Andrews, T Asser, L Balica, C Boeriu, JDC Quintero, ... Trials 10, 1-10, 2009 | 59 | 2009 |
| Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery P Lingasamy, A Tobi, M Haugas, H Hunt, P Paiste, T Asser, T Rätsep, ... Biomaterials 219, 119373, 2019 | 57 | 2019 |
| Changes in viscoelastic properties of skeletal muscles induced by subthalamic stimulation in patients with Parkinson's disease T Rätsep, T Asser Clinical biomechanics 26 (2), 213-217, 2011 | 56 | 2011 |
| A snapshot of European neurosurgery December 2019 vs. March 2020: just before and during the Covid-19 pandemic T Mathiesen, M Arraez, T Asser, N Balak, S Barazi, C Bernucci, C Bolger, ... Acta neurochirurgica 162, 2221-2233, 2020 | 55 | 2020 |
| Prevalence of Parkinson's disease in Estonia P Taba, T Asser Acta neurologica scandinavica 106 (5), 276-281, 2002 | 52 | 2002 |
| Mortality and causes of death after traumatic spinal cord injury in Estonia L Sabre, T Rekand, T Asser, J Kõrv The Journal of Spinal Cord Medicine 36 (6), 687-694, 2013 | 51 | 2013 |
| Emotional health and quality of life after aneurysmal subarachnoid hemorrhage A Vetkas, T Lepik, T Eilat, T Rätsep, T Asser Acta neurochirurgica 155, 1107-1114, 2013 | 49 | 2013 |
| Possible interpretation of subjective complaints in patients with spontaneous subarachnoid haemorrhage. A Toomela, A Pulver, T Tomberg, A Orasson, A Tikk, T Asser Journal of Rehabilitation Medicine 36 (2), 63-69, 2004 | 41 | 2004 |
| Impact of PARP-1 and DNA-PK expression on survival in patients with glioblastoma multiforme M Kase, M Vardja, A Lipping, T Asser, J Jaal Radiotherapy and Oncology 101 (1), 127-131, 2011 | 38 | 2011 |
| Traumatic spinal cord injury in two E uropean countries: why the differences? L Sabre, EM Hagen, T Rekand, T Asser, J Kõrv European journal of neurology 20 (2), 293-299, 2013 | 36 | 2013 |
Pille TabaProfessor of NeurologyEmail được xác minh tại kliinikum.ee
